Skip to main content
Premium Trial:

Request an Annual Quote

Xerion Pharmaceuticals Licenses Antibody Library from Cambridge Antibody Technology

NEW YORK, June 5 - Xerion Pharmaceuticals has agreed to license Cambridge Antibody Technology's library of human phage antibodies for use in drug discovery and functional proteomics, the companies said Tuesday. 

Xerion, based in Martinsried, Germany, will pay CAT an undisclosed license fee for the technology. No other financial details were available. 

"CAT's antibody competence and Xerion's XCALIbur technologies will complement each other exceptionally well and thus create powerful target validation tools," Markus Ewert, CEO of Xerion, said in a statement.

In March, Xerion raised $11.1 million euros ($9.4 million) in a second round private placement, and hired Markus Ewert as CEO from Axxima Pharmaceuticals, another Martinsried-based pharmacueutical company.

CAT, in Cambridge, UK, has licensed its antibody library to a number of pharmaceutical and biotechnology companies, including Genentech, Pfizer, and Immunex.

 
The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.